Loading…
Exagen Inc. is projected to rise to $7.21 by 2027, a +59% move from its current price of $4.53. XGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $4.36 | $4.54 | $4.72 | +0.15% |
| Aug 5 | $4.30 | $4.54 | $4.81 | +0.31% |
| Aug 6 | $4.25 | $4.55 | $4.87 | +0.46% |
| Aug 7 | $4.21 | $4.56 | $4.93 | +0.62% |
| Aug 8 | $4.18 | $4.56 | $4.99 | +0.77% |
| Aug 9 | $4.15 | $4.57 | $5.04 | +0.93% |
| Aug 10 | $4.12 | $4.58 | $5.08 | +1.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.12 | $4.58 | $5.08 | +1.08% |
| Week 2 | $3.99 | $4.63 | $5.37 | +2.18% |
| Week 3 | $3.90 | $4.68 | $5.61 | +3.28% |
| Week 4 | $3.84 | $4.73 | $5.83 | +4.40% |
| Week 5 | $3.78 | $4.78 | $6.04 | +5.53% |
| Week 6 | $3.74 | $4.83 | $6.24 | +6.68% |
| Week 7 | $3.70 | $4.88 | $6.44 | +7.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Exagen Inc. designs, develops, and commercializes AVISE testing products in the United States. Its work focuses on diagnosing, prognosing, and monitoring complex rheumatic and autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
The company’s lead testing product is AVISE CTD, which enables differential diagnosis for patients with symptoms of various connective tissue diseases and related conditions. Exagen offers AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE Anti-Histone, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE SLE Monitor, AVISE MTX, and AVISE HCQ, among other tests to support physician care.
Exagen was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. It was incorporated in 2002 and is headquartered in Vista, California. The company also has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers.
Exagen Inc. (XGN) operates in the Healthcare sector with a current price of $4.67 and a market cap of $112.83M. It is ranked 3900 by market capitalization among its peers. The stock’s current price and market position place it in a small-cap healthcare niche.
The price outlook reflects a path of rising average values over the forecast horizon. The 2026 avg price is $4.67, rising to $11.51 by 2030, then climbing to $53.83 by 2040 and to $114.62 by 2050, suggesting substantial long‑term upside potential from the current level.
A major floor 41.5% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 18.8% above — clearing it would confirm fresh momentum.
Key XGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.48 | Buy | $4.55 | Sell |
| MA 10 | $4.65 | Sell | $4.56 | Sell |
| MA 20 | $4.52 | Buy | $4.54 | Sell |
| MA 50 | $4.54 | Sell | $4.38 | Buy |
| MA 100 | $3.80 | Buy | $4.37 | Buy |
| MA 200 | $5.26 | Sell | $4.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.39 | Neutral |
| Stoch RSI (14) | 40.84 | Neutral |
| CCI (20) | 4.62 | Neutral |
| Williams %R (14) | -48.84 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 5.35 | Buy |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 51.16 | Neutral |
| TRIX (15) | 0.14 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 42.72 | Neutral |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 4.42 | Buy |
| ADX (14) | 9.08 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture shows a bullish tilt in the near term. RSI14 sits at 50, with the price hovering near the SMA50 of $4.53 and below the SMA200 of $5.30. This setup places initial near-term resistance at $4.95 and support at $4.09, with the current range spanning from $3.58 to $6.09 over the last 30 days.
The stock’s 30-day range implies meaningful movement potential, while the 80% annualized volatility signals elevated fluctuations. The current price sits within this context, suggesting a balanced but finely poised setup for a move toward the nearby resistance if momentum improves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.65 | $4.53 | $7.49 | 0% | Neutral | |
| $5.51 | $7.21 | $10.08 | +59% | Bullish | |
| $6.76 | $9.22 | $13.59 | +104% | Bullish | |
| $7.63 | $10.80 | $16.54 | +138% | Bullish | |
| $7.29 | $10.64 | $16.85 | +135% | Bullish | |
| $8.51 | $12.80 | $20.86 | +183% | Bullish | |
| $10.19 | $15.76 | $26.33 | +248% | Bullish | |
| $12.87 | $20.43 | $34.91 | +351% | Bullish | |
| $15.53 | $25.28 | $44.11 | +458% | Bullish | |
| $14.47 | $24.13 | $42.90 | +433% | Bullish | |
| $24.69 | $46.13 | $88.80 | +918% | Bullish | |
| $43.25 | $96.12 | $207.18 | +20.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.65 | $4.53 | $5.93 | +0.00% |
| September 2026 | $4.15 | $4.97 | $6.16 | +9.66% |
| October 2026 | $4.31 | $5.21 | $6.57 | +4.93% |
| November 2026 | $4.65 | $5.67 | $7.23 | +8.77% |
| December 2026 | $4.73 | $5.81 | $7.49 | +2.51% |
Click any year to see its month-by-month XGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, XGN could reach as high as $7.49, with a base case around $4.53 and support toward $2.65 — roughly 0% from $4.53. Price action looks broadly range-bound.
Expect XGN to range from $5.51 to $10.08 through 2027. The $7.21 average target implies a +59% move from current prices. That is up +59% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The XGN price prediction for 2028 points to an average of $9.22 (low $6.76, high $13.59) — a potential gain of +104% on today's $4.53. Momentum favours further upside here.
In 2029, XGN is projected to trade between $7.63 and $16.54, averaging $10.80 — a potential gain of +138% from today's $4.53. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Exagen Inc.'s 2030 outlook centres on $10.64, within a $7.29 to $16.85 range. That is -1% versus the projected 2029 average. That marks a +135% change versus current levels. Momentum favours further upside here.
By 2031, XGN could reach as high as $20.86, with a base case around $12.80 and support toward $8.51 — roughly +183% from $4.53. Buyers look set to stay in control over this stretch.
Expect XGN to range from $10.19 to $26.33 through 2032. The $15.76 average target implies a +248% move from current prices. That is up +23% on the projected 2031 average. Momentum favours further upside here.
The XGN price prediction for 2033 points to an average of $20.43 (low $12.87, high $34.91) — a potential gain of +351% on today's $4.53. Buyers look set to stay in control over this stretch.
In 2034, XGN is projected to trade between $15.53 and $44.11, averaging $25.28 — a potential gain of +458% from today's $4.53. That is up +24% on the projected 2033 average. Momentum favours further upside here.
Exagen Inc.'s 2035 outlook centres on $24.13, within a $14.47 to $42.90 range. That is -5% versus the projected 2034 average. That marks a +433% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, XGN could reach as high as $88.80, with a base case around $46.13 and support toward $24.69 — roughly +918% from $4.53. Momentum favours further upside here.
Expect XGN to range from $43.25 to $207.18 through 2050. The $96.12 average target implies a +20.2x move from current prices. That is up +108% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in XGN today (≈ 220.750552 XGN) could be worth
$21,217.54
+$20,217.54 (+2022%) by 2050 · US Dollar
Based on the average projected XGN price of $96.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XGNwould be worth at today's price.
$1,000 invested in XGN on Jul 31, 2025 (≈ 119.047624 XGN) would be worth
$539.29
-$460.71 (-46.1%) today · 0.54× · US Dollar
Based on a XGN entry price of $8.4 vs. today's $4.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.68 | $967.95 | -3.2% |
| 1 month ago | $4.71 | $961.78 | -3.8% |
| 3 months ago | $3.06 | $1,480.39 | +48.0% |
| 6 months ago | $3.83 | $1,182.77 | +18.3% |
| 1 year ago | $8.4 | $539.29 | -46.1% |
| All time (5.0y) ago | $11.35 | $399.12 | -60.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XGN forecast.
Our base-case forecast reaches $9.10 around 2028.
Implied market cap at $9.10: $219.85M
The multi-year forecast shows a steady rise in the average price from 2026 through 2050. It projects an average of $4.67 in 2026, $7.60 in 2027, $9.84 in 2028, $11.58 in 2029, and $11.51 in 2030, then higher averages of $14.09 (2031), $17.60 (2032), $22.98 (2033), $28.56 (2034), and $27.12 (2035).
Beyond 2035, the forecast envisions continued strength with an average of $53.83 in 2040 and $114.62 in 2050. Corresponding ROI figures rise from 0% in 2026 to 62.7% (2027), 110.8% (2028), 147.9% (2029), 146.6% (2030), 201.8% (2031), 277% (2032), 392.1% (2033), 511.5% (2034), 480.6% (2035), 1052.6% (2040), and 2354.3% (2050). The sentiment remains BULLISH across the horizon, with 2026 labeled NEUTRAL.
These are projection estimates, not guarantees, and reflect the stated price paths and upside potential with acknowledged uncertainty and market volatility.
Tap a question to reveal the answer.
The forecast shows an average price of $11.51 in 2030, with a min of $7.85 and a max of $18.32. The ROI is 146.6% and the sentiment is BULLISH.
Forecasts indicate the average price rising from $4.67 in 2026 to $11.51 in 2030, with bullish sentiment in later years and positive ROI figures (e.g., 62.7% in 2027, 110.8% in 2028, 147.9% in 2029, and higher thereafter). These are estimates, not guarantees.
Yes. The forecast shows a max of $50.12 in 2034, meaning the asset could exceed $50 by 2034 according to these numbers.
Current price is $4.67 and market cap is $112.83M.
For 2040, the forecast shows an avg price of $53.83, a max of $104.36, and ROI of 1052.6%; sentiment is BULLISH.
Exagen Inc. Community Discussion
0Share your Exagen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.